Catabasis Pharmaceuticals, Inc.

Catabasis did not report revenue. It reported Q4 2019 net loss of $6.6 million, or $0.55 per share, versus a net loss that was $0.5 million lower in Q4 2018; full-year 2019 net loss was $26.3 million versus $25.9 million in 2018. Q4 2019 R&D expense was $4.3 million versus $3.7 million a year ago, and G&A was $2.5 million versus $2.4 million; full-year R&D was $18.3 million versus $17.0 million, and G&A was $8.8 million versus $9.3 million. Cash, cash equivalents and short-term investments were $36.2 million at Dec. 31, 2019, and the company raised an additional $25.6 million in net proceeds after quarter-end. Net cash used in operating activities was $7.8 million in Q4 and $26.6 million for the full year. Looking ahead, management expects top-line PolarisDMD Phase 3 results in Q4 2020, a potential NDA filing in 2021, and says current resources should fund operations through that filing and into Q3 2021. They also said quarterly net losses should be higher than Q4 2019 and increase through 2020 due to PolarisDMD, GalaxyDMD, NDA prep, and commercial preparations.

Jill Milne framed 2019 as a year of strong progress for edasalonexent and emphasized the drug’s broad Duchenne thesis: an NF-kB mechanism intended to help all patients regardless of mutation, including skeletal muscle, cardiac, and bone outcomes. She highlighted the company’s shift toward commercialization readiness, the partnership with Duchenne UK for non-ambulatory patients, and the plan to reserve future calls for clinical data and major events rather than routine quarterly updates. Her tone was confident but measured, with repeated emphasis on the pending Phase 3 readout as the key catalyst.

Noah Clauser focused on liquidity, spend, and the burn outlook. He said Catabasis had $36.2 million in cash, cash equivalents and short-term investments at Dec. 31, 2019, then added $25.6 million in net proceeds from an equity financing after quarter-end, and reiterated the company expects to fund operations through a potential NDA filing and into Q3 2021. He also detailed operating costs: Q4 2019 R&D of $4.3 million, G&A of $2.5 million, Q4 net loss of $6.6 million, and full-year operating cash use of $26.6 million. He warned that quarterly net losses should rise through 2020 as clinical, regulatory, and commercial work ramps.

Analysts focused on how many PolarisDMD patients had rolled into GalaxyDMD, whether conference cancellations from coronavirus could delay data disclosure, and whether the trials were seeing any COVID-related disruptions. Management said the Galaxy enrollment count changes weekly and declined to give an exact number, but noted enrollment has been strong and that Galaxy is still ramping. On coronavirus, they said they were monitoring the situation, had plans to address disruptions, were not aware of infections near the trial, and noted the three-month visit cadence gives them some flexibility. Another set of questions probed commercial readiness, CMC/supply chain plans, toxicology completion for an NDA, and pricing/ISR; management said manufacturing will rely on third-party providers, non-clinical tox programs are progressing well, and pricing discussions are still early while they continue dialogue with payers and KOLs.